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Abstract Proteolytic systems have various involvements in
apoptotic pathways. To understand the role of calpain in
apoptosis, calpastatin, a specific inhibitor of calpain, was
overexpressed in human UVr-1 fibroblasts by transfection of its
cDNA. The elevated expression of calpastatin resulted in
decreased survival in the presence of okadaic acid (OA) but in
no apparent alteration in the sensitivity toward other drugs such
as 5-fluorouracil, mitomycin C and methotrexate. After treat-
ment with OA, a typical apoptotic DNA ladder was observed in
control vector-transfected cells but not in calpastatin-transfected
cells. This indicates that OA-induced apoptosis was suppressed
by overexpression of calpastatin. Further immunoblot analysis
showed that the OA-induced hyperphosphorylation of c-Jun was
inhibited in calpastatin-transfected cells. This might be involved
in the resistance to OA-induced cell death in calpastatin-
overproducing cells.
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1. Introduction
Apoptotic cell death is regulated by a variety of molecules.
Anti-apoptotic activity was reported for Bcl-2, Akt and ERK
mitogen-activated protein kinases (MAP kinases), whereas
pro-apoptotic e¡ects were observed for p53, Bax, Bad,
stress-activated protein kinase/Jun N-terminal kinase
(SAPK/JNK) and p38 MAP kinase (for review see [1]). The
apoptotic pathway is also regulated by proteases such as cas-
pases, calpains and proteasome [2]. Calpains are of great in-
terest since they have been reported to cleave signaling mole-
cules including protein kinase C, Src, epidermal growth factor
receptor, c-Jun, c-Fos, p53, etc. [3^8]. Two major calpains, W-
calpain and m-calpain, are ubiquitously expressed, and the
activity of both calpains is speci¢cally inhibited by calpastatin
[9]. A synthetic calpain inhibitor, acetyl-Leu-Leu-norleucinal
(ALLN), has frequently been used for investigating the roles
of calpains [10]. ALLN induced apoptosis in human prostate
adenocarcinoma cells [11] and human HL-60 promyelocytic
leukemia cells [12], whereas it showed anti-apoptotic activity
on transforming growth factor L-induced apoptosis in rat
hepatocytes [13] and N-methyl-D-aspartate-induced apoptotic
cell death in human CHP100 neuroblastoma cells [14]. Thus,
the role of calpain in apoptosis is controversial.
Okadaic acid (OA) is a potent inhibitor of protein phos-
phatase 1 and protein phosphatase 2A [15], and is a useful
probe for the study of cellular phosphorylation regulation
[16]. Treatment with OA resulted in apoptotic cell death
which was accompanied by hyperphosphorylation of c-Jun
[17], induction of p21Cip1 and Bax [18] and modulation of
Raf-1, protein kinase C and MAP kinases [19]. It remains
to be clari¢ed which of these signaling molecules has a key
role in OA-induced apoptosis.
In this study, to examine the role of calpains in OA-induced
apoptosis, calpastatin cDNA was transfected into human ¢-
broblast UVr-1 cells. The overexpression of calpastatin re-
sulted in a marked suppression of apoptosis induced by treat-
ment with OA. Possible involvement of Bad and MAP kinases
is discussed.
2. Materials and methods
2.1. Materials
Okadaic acid and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) were purchased from Sigma (St. Louis, MO,
USA).
2.2. Cell culture
The human cell strain RSa is an embryonic ¢broblastic strain trans-
formed by infection with Rous sarcoma virus and simian virus 40 [20].
UVr-1 cells were derived from RSa cells mutated with ethyl methane-
sulfonate, then treated with UV followed by selection of surviving
cells [21]. These cells were cultured in a medium containing Eagle’s
MEM supplemented with 10% calf serum.
2.3. Transfection of calpastatin
Human calpastatin cDNA [22] was inserted into the XbaI site of
pRc/CMV eukaryotic expression vectors (Invitrogen) and transfected
into UVr-1 cells using LipofectAMINE reagent (Life Technologies).
Transfected cells were selected in the presence of G418 (400 Wg/ml) for
2 weeks.
2.4. Methods for assessing cell survival
Cells in the logarithmic growing phase (5U103) were plated in each
well of 96-well plates containing various concentrations of OA, 5-
£uorouracil (5-FU), mitomycin C (MMC) and methotrexate (MTX),
and cultured for 3 days according to the method of Mosmann [23] as
described previously [24]. The activity of mitochondrial succinic de-
hydrogenase was measured by incubation for 4 h in the presence of
MTT (0.5 mg/ml) followed by measurement of absorbance at 570 nm
with a reference wavelength of 655 nm. Absorbance re£ects the viable
cell number, and the relative viability was expressed as a percentage of
control cells cultured in the absence of test drugs.
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2.5. DNA fragmentation analysis
Cells were cultured for 48 h in the presence of OA at concentrations
of 0, 5, 10, 15 and 20 nM, and then lysed for 3 h at 37‡C in a solution
containing 50 mM Tris-HCl (pH 8.0), 2 mM EDTA, 1% SDS and
100 Wg/ml proteinase K. Following high-molecular-weight DNA pre-
cipitation by the addition of 7/10 volume 2-propanol and centrifuga-
tion at 15 000 rpm for 5 s at room temperature, the low-molecular-
weight DNA was recovered from the supernatant and precipitated by
incubation overnight at 320‡C. After centrifugation, the precipitate
was re-suspended and treated with DNase-free RNase A for 3 h at
37‡C. The samples were electrophoresed on 1.5% agarose gel contain-
ing 0.5 Wg/ml ethidium bromide [25].
2.6. Preparation of cell extract and immunoblot analysis
Cells were treated with OA at a concentration of 10 nM for 24 h.
Control cells were without treatment. Cells were then washed with
phosphate-bu¡ered saline three times and incubated in lysis bu¡er
(0.5% Nonidet P-40, 20 mM Tris-HCl (pH 7.5), 1 mM EDTA,
1 mM EGTA, 1 mM phenylmethylsulfonyl £uoride, 50 WM leupeptin,
50 WM antipain, 50 WM pepstatin A and 50 WM ALLN) for 10 min at
4‡C. The cell lysate was centrifuged at 13 000Ug for 10 min and the
supernatant was analyzed by immunoblot using anti-calpastatin (Ta-
kara, Kyoto, Japan), anti-phospho-speci¢c SAPK and anti-phospho-
speci¢c c-Jun antibodies (New England Biolabs, Beverly, MA, USA).
The reaction was detected using the ECL system (Amersham) as de-
scribed previously [26,27].
3. Results
3.1. Transfection of calpastatin cDNA
Human calpastatin cDNA was inserted into the constitutive
expression vector pRc/CMV and transfected into UVr-1 cells.
The expression of calpastatin in G418-selected clones was ex-
amined by immunoblot. Two bands were observed, possibly
due to the di¡erent phosphorylation levels of calpastatin (Fig.
1) [28]. One of the transfected clones, UCST-4, expressed an
elevated level of calpastatin relative to an empty vector-trans-
fected control clone, UCMV-4. Thus, these two clones were
used in the following experiments.
3.2. Di¡erent chemosensitivity to OA between control and
calpastatin-transfected cells
To investigate the chemosensitivity to cytotoxic drugs of
control and calpastatin-transfected cells, the relative number
of viable cells after culture for 3 days in the presence of vary-
ing concentrations of the drugs was measured by the MTT
method. OA suppressed the proliferation of UCMV-4 cells
more e¡ectively than UCST-4 cells (Fig. 2A). Half-maximum
inhibition concentrations (IC50) of OA were 6 and 10 nM in
UCMV-4 and UCST-4 cells, respectively. On the other hand,
chemosensitivity toward 5-FU, MMC and MTX was not sig-
ni¢cantly di¡erent between UCMV-4 and UCST-4 cells (Fig.
2B^D). Thus, the reduced sensitivity of UCST-4 cells was
speci¢c to OA.
3.3. Comparison of OA-induced DNA fragmentation between
control and calpastatin-transfected cells
To investigate further the di¡erent sensitivities to OA be-
tween UCMV-4 and UCST-4 cells, we investigated internu-
cleosomal DNA cleavage, a typical event in apoptosis [29].
Fig. 1. Expression of calpastatin in calpastatin-transfected clones.
Cytoplasmic cell extracts of a calpastatin-transfected clone, UCST-4,
and a vector-transfected clone, UCMV-4, were analyzed by immu-
noblot using anti-calpastatin antibody.
Fig. 2. E¡ects of OA on the proliferation of UCMV-4 and UCST-4 cells. UCMV-4 (open circles) and UCST-4 cells (closed circles) were cul-
tured for 3 days in the presence of varying concentrations of OA (A), 5-FU (B), MMC (C) and MTX (D). After incubation with MTT, ab-
sorbance at 570 nm, re£ecting the viable cell number, was measured and expressed as a percentage of that in the absence of inhibitors. Data
are means of two experiments.
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DNA was isolated from cells 48 h after addition of OA and
analyzed by agarose gel electrophoresis. Treatment with OA
at concentrations of 10, 15 and 20 nM resulted in the appear-
ance of a typical DNA ladder in UCMV-4 cells (Fig. 3).
However, no obvious discrete DNA band was observed in
UCST-4 cells treated with OA at any concentration. Thus,
OA was unable to induce apoptosis in calpastatin-transfected
cells. Some decrease in survival of UCST-4 cells at OA con-
centrations higher than 10 nM (Fig. 2A) might re£ect necrotic
cell death.
3.4. Immunoblot analysis of signaling molecules after treatment
with OA
Immunoblot analysis was performed to investigate the ex-
pression levels of signaling molecules. UCMV-4 and UCST-4
cells were treated with OA at 10 nM for 24 h. Cells extracts
were prepared as described in Section 2. Activated c-Jun can
be detected by the antibody which speci¢cally recognizes
phosphorylation at serine-63 of c-Jun. Although the level of
phosphorylated c-Jun was similar between untreated UCMV-
4 and UCST-4 cells, it increased in UCMV-4 cells 24 h after
addition of OA but not in UCST-4 cells (Fig. 4A). The hyper-
phosphorylation of c-Jun was clearly observed as shifted
bands in OA-treated UCMV-4 cells.
It has been reported that serine-63 of c-Jun is phosphoryl-
ated by active SAPK [30]. Activated SAPK was observed by a
speci¢c antibody that recognized phosphorylation at threo-
nine-183 and tyrosine-185 [30] (Fig. 4B). The level of activated
SAPK was higher in UCMV-4 cells than in UCST-4 cells
without OA treatment. The activated SAPK increased after
addition of OA in both cells but the level in UCMV-4 was still
higher than that in UCST-4 cells.
No apparent change in the expression levels of p53, Bax,
Bad and activated ERK1 in the nuclear and cytoplasmic frac-
tions was observed after treatment with OA in both UCMV-4
and UCST-4 cells (data not shown). The expressions of
p21Cip1 and Bcl-2 were under the detectable levels in both cells
irrespective of OA treatment (data not shown).
4. Discussion
Sheikh et al. reported that treatment with OA resulted in
nuclear accumulation of p53, p21Cip1 and Bax which might be
related to the subsequent apoptotic cell death of human breast
carcinoma cells [18]. Dimerization of Bax was reported to be
su⁄cient for induction of apoptosis [31]. However, our
present study showed that none of these molecules increased
or was translocated into the nuclei in UVr-1 cells after treat-
ment with OA (data not shown). Among pro-apoptotic mol-
ecules thus far examined, activated SAPK increased 24 h after
OA treatment in UCMV-4 cells (Fig. 4B). Although p53 was
reported to be phosphorylated by SAPK [32], no signi¢cant
di¡erence in the level of nuclear or cytoplasmic p53 was ob-
served (data not shown). Furthermore, the levels of p21Cip1
and Bax, which can be induced by p53, were not altered by
treatment with OA (data not shown). These data suggest that
the signaling pathway via p53 was not induced by OA in this
cell. However, consistent with the previous report of Peng et
al. [17], c-Jun was hyperphosphorylated 24 h after addition of
OA in UCMV-4 cells, but not in UCST-4 cells (Fig. 4A).
Therefore, it is possible that hyperphosphorylation of c-Jun
accounts, in part, for the induction of apoptosis in UCMV-4
cells. It should be noted that SAPK/JNK activation was fol-
lowed by induction of Fas ligand in PC12 cells [33]. Thus,
SAPK-to-c-Jun-to-Fas ligand could be a major pathway for
OA-induced apoptosis. Overexpression of calpastatin might
interrupt this signaling pathway.
Calpains are involved in proteolytic down-regulation of ac-
tivated protein kinases such as protein kinase C, c-Src and
epidermal growth factor receptor [3^5]. It is thus reasonable
to speculate that suppression of calpain activity by calpastatin
might enhance signal transduction. However, activation of c-
Jun was reduced in calpastatin-transfected cells despite some
increase in the level of activated SAPK (Fig. 4A,B). This
raises the possibility that calpain is not only a suppressive
molecule, but can potentiate a signaling pathway through
SAPK. Activation of the substrates by calpains was also sug-
gested by Carafoli and Molinari based on the fact that calpain
cleaved the substrates into a small number of well de¢ned
fragments [8]. Further investigation will elucidate the direct
role of calpain in the apoptotic signaling pathway.
Fig. 3. Induction of DNA fragmentation by OA. UCMV-4 and
UCST-4 cells were treated with OA at 0, 5, 10, 15 and 20 nM for
48 h. DNA was isolated and analyzed on 1.5% agarose/ethidium
bromide gel. M represents DNA size marker (V/HindIII).
Fig. 4. E¡ects of OA on the expression of signaling molecules.
UCMV-4 and UCST-4 cells were treated with OA at a concentra-
tion of 10 nM for 24 h and the cell extracts were analyzed by im-
munoblot using phospho-speci¢c anti-c-Jun (A) and phospho-specif-
ic anti-SAPK (B) antibodies. The results without OA treatment are
also shown (3).
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